162 related articles for article (PubMed ID: 35349180)
21. Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system.
Lin W; Xu J; Liao Y; Lin X; Yang J; Zhuang W
Int J Clin Pharm; 2024 Jun; 46(3):614-622. PubMed ID: 38100054
[TBL] [Abstract][Full Text] [Related]
22. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
Chodak G; Sharifi R; Kasimis B; Block NL; Macramalla E; Kennealey GT
Urology; 1995 Dec; 46(6):849-55. PubMed ID: 7502428
[TBL] [Abstract][Full Text] [Related]
23. [Changes in liver function induced by flutamide in patients with prostate cancer (studies in patients treated with total androgen blockage)].
Ikemoto I; Ohishi Y; Yamazaki H; Wada T; Aizawa Y
Nihon Hinyokika Gakkai Zasshi; 2000 Jun; 91(6):556-61. PubMed ID: 10897581
[TBL] [Abstract][Full Text] [Related]
24. First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.
Prescrire Int; 2013 Feb; 22(135):48-51. PubMed ID: 23444510
[TBL] [Abstract][Full Text] [Related]
25. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports.
Fernández AB; Karas RH; Alsheikh-Ali AA; Thompson PD
Chest; 2008 Oct; 134(4):824-830. PubMed ID: 18689579
[TBL] [Abstract][Full Text] [Related]
26. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the potential complication of interstitial lung disease associated with antifibrotic drugs using data from databases reporting spontaneous adverse effects.
Nawa H; Hamano H; Niimura T; Miyata K; Yagi K; Goda M; Zamami Y; Ishizawa K
Clin Transl Sci; 2022 Dec; 15(12):2982-2988. PubMed ID: 36128688
[TBL] [Abstract][Full Text] [Related]
28. Degarelix Versus Goserelin Plus Bicalutamide in the Short-Term Relief of Lower Urinary Tract Symptoms in Prostate Cancer Patients: Results of a Pooled Analysis.
Mason M; Richaud P; Bosnyak Z; Malmberg A; Neijber A
Low Urin Tract Symptoms; 2017 May; 9(2):82-88. PubMed ID: 28394498
[TBL] [Abstract][Full Text] [Related]
29. Comparison of goserelin and leuprolide in combined androgen blockade therapy.
Sarosdy MF; Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Vogelzang NJ; Chodak GW; Klein EA; Schellenger JJ; Kolvenbag GJ
Urology; 1998 Jul; 52(1):82-8. PubMed ID: 9671875
[TBL] [Abstract][Full Text] [Related]
30. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
31. Nilutamide: an antiandrogen for the treatment of prostate cancer.
Dole EJ; Holdsworth MT
Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470
[TBL] [Abstract][Full Text] [Related]
32. Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
Takizawa I; Hara N; Nishiyama T; Isahaya E; Hoshii T; Takahashi K
J Urol; 2010 Nov; 184(5):1971-6. PubMed ID: 20884032
[TBL] [Abstract][Full Text] [Related]
33. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.
Sugiono M; Winkler MH; Okeke AA; Benney M; Gillatt DA
Prostate Cancer Prostatic Dis; 2005; 8(1):91-4. PubMed ID: 15711607
[TBL] [Abstract][Full Text] [Related]
34. Interstitial pneumonitis related to flutamide monotherapy for prostate cancer.
Nomura M; Sato H; Fujimoto N; Matsumoto T
Int J Urol; 2004 Sep; 11(9):798-800. PubMed ID: 15379950
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
Efstathiou JA; Bae K; Shipley WU; Hanks GE; Pilepich MV; Sandler HM; Smith MR
Eur Urol; 2008 Oct; 54(4):816-23. PubMed ID: 18243498
[TBL] [Abstract][Full Text] [Related]
36. Primary Androgen-Depletion Therapy Prevails Not Only for Metastatic but Also for Nonmetastatic Hormone-Naïve Prostate Cancer in Japan-Recent Trends and Efficacy.
Onozawa M; Hinotsu S; Saito A; Uno S; Akaza H
Gan To Kagaku Ryoho; 2021 Jul; 48(7):911-919. PubMed ID: 34267028
[TBL] [Abstract][Full Text] [Related]
37. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.
Fair WR; Cookson MS; Stroumbakis N; Cohen D; Aprikian AG; Wang Y; Russo P; Soloway SM; Sogani P; Sheinfeld J; Herr H; Dalgabni G; Begg CB; Heston WD; Reuter VE
Urology; 1997 Mar; 49(3A Suppl):46-55. PubMed ID: 9123736
[TBL] [Abstract][Full Text] [Related]
38. Testosterone suppression in men with prostate cancer is associated with increased arterial stiffness.
Dockery F; Bulpitt CJ; Agarwal S; Rajkumar C
Aging Male; 2002 Dec; 5(4):216-22. PubMed ID: 12630068
[TBL] [Abstract][Full Text] [Related]
39. Intermittent versus continuous androgen deprivation in prostate cancer.
Hussain M; Tangen CM; Berry DL; Higano CS; Crawford ED; Liu G; Wilding G; Prescott S; Kanaga Sundaram S; Small EJ; Dawson NA; Donnelly BJ; Venner PM; Vaishampayan UN; Schellhammer PF; Quinn DI; Raghavan D; Ely B; Moinpour CM; Vogelzang NJ; Thompson IM
N Engl J Med; 2013 Apr; 368(14):1314-25. PubMed ID: 23550669
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular Adverse Events Associated With New-Generation Androgen Receptor Pathway Inhibitors (ARPI) for Prostate Cancer: A Disproportionality Analysis Based on the FDA Adverse Event Reporting System (FAERS).
Liu Y; Zhang HM; Jiang Y; Wen Z; Bao EH; Huang J; Wang CJ; Chen CX; Wang JH; Yang XS
Clin Genitourin Cancer; 2023 Oct; 21(5):594-601.e2. PubMed ID: 37482524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]